Shares of Gilead Sciences Inc. GILD rose 1.60% to $107.62 Thursday, on what proved to be an all-around great trading session ...

Merck announced ACIP voted to recommend Enflosnia (clesrovimab-cfor) as a treatment option for RSV in infants younger than 8 months of age who are born during or entering their first RSV season.

Yeztugo (lenacapavir) will be the first option that gives people who need or want PrEP the option of injecting only twice a ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A ...

President Donald Trump, ever the negotiator, is angling to lower drug prices through his Most Favored Nation policy. But will ...

Friday is National HIV Testing Day, and it's an issue that's very important to metro Atlanta. Actor and advocate Miss ...

Gilead has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two mid-stage trials of ...

An injection that can prevent HIV infection for six months has been approved by the US Food and Drug Administration (FDA).